logo
  

AbbVie Receives Option To License Certain IL-2 Muteins, Including CUG252, From Cugene

AbbVie (ABBV) and Cugene Inc. announced a worldwide license option agreement for CUG252, a potential Treg-selective IL-2 mutein, as well as other IL-2 muteins, for the potential treatment of autoimmune and inflammatory diseases. During the option period, Cugene will conduct a phase 1b study in patients with autoimmune/inflammatory disease. Upon exercise of the option, AbbVie will conduct all future clinical development, manufacturing and commercialization activities for CUG252.

Cugene will receive an upfront payment of $48.5 million, and will also be eligible to receive development and regulatory milestones and a license option exercise payment if AbbVie exercises the option. Also, Cugene may receive commercialization and sales-based milestones and tiered royalties.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Tesla Inc. founder and CEO Elon Musk has sold some of his stake in the luxury electric car maker to avoid an emergency sale of its stock in the event of a forceful Twitter deal. Twitter Inc. and Tesla shares were gaining more than 4 percent in the pre-market activity on the NYSE and Nasdaq, respectively, following the news. Meta Platforms Inc., the parent of Facebook, Instagram, and WhatsApp, has added three more new privacy features to WhatsApp in its bid to enhance control and privacy on the popular messaging app. These features will give the user more control over their messages with added interlocking layers of protection. Insurance company Prudential plc reported Wednesday a sharp drop in first-half pre-tax profit. On an after-tax basis, the company recorded a profit, compared to last year's hefty loss, due to the absence of prior year's loss from discontinued operations. Separately, Prudential announced its 2022 first interim dividend of 5.74 US cents per ordinary share, which will be paid on September 27.
Follow RTT